Global Diagnostic Nuclear Medicines Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Diagnostic Nuclear Medicines Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Diagnostic radiopharmaceuticals. Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
Diagnostic Nuclear Medicines report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diagnostic Nuclear Medicines market is projected to reach US$ 7534.8 million in 2029, increasing from US$ 4722 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Demand from Oncology and Cardiology are the major drivers for the industry.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Nuclear Medicines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Oncology
Cardiology
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Diagnostic Nuclear Medicines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Diagnostic Nuclear Medicines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Diagnostic Nuclear Medicines industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Diagnostic Nuclear Medicines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Diagnostic Nuclear Medicines introduction, etc. Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Diagnostic Nuclear Medicines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Diagnostic Nuclear Medicines report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diagnostic Nuclear Medicines market is projected to reach US$ 7534.8 million in 2029, increasing from US$ 4722 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Demand from Oncology and Cardiology are the major drivers for the industry.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Nuclear Medicines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Segment by Application
Oncology
Cardiology
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Diagnostic Nuclear Medicines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Diagnostic Nuclear Medicines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Diagnostic Nuclear Medicines industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Diagnostic Nuclear Medicines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Diagnostic Nuclear Medicines introduction, etc. Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Diagnostic Nuclear Medicines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices